Zirakchian Zadeh Mahdi, Yeh Randy, Kunin Henry S, Kirov Assen S, Petre Elena N, Gönen Mithat, Silk Mikhail, Cornelis Francois H, Soares Kevin C, Ziv Etay, Solomon Stephen B, Sotirchos Vlasios S, Sofocleous Constantinos T
Interventional Radiology/Oncology Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Cancers (Basel). 2022 Dec 19;14(24):6253. doi: 10.3390/cancers14246253.
Real-time split-dose PET can identify the targeted colorectal liver metastasis (CLM) and eliminate the need for repeated contrast administration before and during thermal ablation (TA). This study aimed to assess the added value of pre-ablation real-time split-dose PET when combined with non-contract CT in the detection of CLM for ablation and the evaluation of the ablation zone and margins.
A total of 190 CLMs/125 participants from two IRB-approved prospective clinical trials using PET/CT-guided TA were analyzed. Based on detection on pre-TA imaging, CLMs were categorized as detectable, non-detectable, and of poor conspicuity on CT alone, and detectable, non-detectable, and low FDG-avidity on PET/CT after the initial dose. Ablation margins around the targeted CLM were evaluated using a 3D volumetric approach.
We found that 129/190 (67.9%) CLMs were detectable on CT alone, and 61/190 CLMs (32.1%) were undetectable or of poor conspicuity, not allowing accurate depiction and targeting by CT alone. Thus, the theoretical 5- and 10-mm margins could not be defined in these tumors (32.1%) using CT alone. When TA intraprocedural PET/CT images are obtained and inspected (fused PET/CT), only 4 CLM (2.1%) remained undetectable or had a low FDG avidity.
The addition of PET to non-contrast CT improved CLM detection for ablation targeting, margin assessments, and continuous depiction of the FDG avid CLMs during the ablation without the need for multiple intravenous contrast injections pre- and intra-procedurally.
实时分剂量PET能够识别靶向性结直肠癌肝转移灶(CLM),并且无需在热消融(TA)前和消融过程中重复注射造影剂。本研究旨在评估消融前实时分剂量PET联合非增强CT在检测用于消融的CLM以及评估消融区和边缘方面的附加价值。
对来自两项经机构审查委员会批准的使用PET/CT引导TA的前瞻性临床试验的190个CLM/125名参与者进行了分析。根据TA前成像的检测结果,CLM被分类为在CT上可检测到、不可检测到以及仅在CT上显示不清,以及在初始剂量后的PET/CT上可检测到、不可检测到和FDG摄取低。使用三维容积法评估靶向CLM周围的消融边缘。
我们发现,190个CLM中有129个(67.9%)仅在CT上可检测到,61个CLM(32.1%)不可检测到或显示不清,仅靠CT无法准确描绘和定位。因此,仅使用CT无法在这些肿瘤(32.1%)中定义理论上的5毫米和10毫米边缘。当获取并检查TA术中PET/CT图像(融合PET/CT)时,只有4个CLM(2.1%)仍不可检测到或FDG摄取低。
在非增强CT基础上加用PET可改善用于消融靶向的CLM检测、边缘评估,并在消融过程中持续描绘FDG摄取的CLM,而无需在术前和术中多次静脉注射造影剂。